4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Net Margin for 6 consecutive years, with 63195.56% as the latest value for Q3 2025.
- On a quarterly basis, Net Margin rose 139823778.0% to 63195.56% in Q3 2025 year-over-year; TTM through Sep 2025 was 174314.17%, a 66968583.0% increase, with the full-year FY2024 number at 434778.38%, down 43429178.0% from a year prior.
- Net Margin was 63195.56% for Q3 2025 at 4D Molecular Therapeutics, up from 364386.67% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 169910.53% in Q4 2023 to a low of 4967100.0% in Q4 2024.
- A 5-year average of 416963.24% and a median of 12391.63% in 2023 define the central range for Net Margin.
- Peak YoY movement for Net Margin: tumbled -513701053bps in 2024, then soared 139823778bps in 2025.
- 4D Molecular Therapeutics' Net Margin stood at 27264.13% in 2021, then skyrocketed by 92bps to 2193.83% in 2022, then skyrocketed by 7845bps to 169910.53% in 2023, then plummeted by -3023bps to 4967100.0% in 2024, then surged by 99bps to 63195.56% in 2025.
- Per Business Quant, the three most recent readings for FDMT's Net Margin are 63195.56% (Q3 2025), 364386.67% (Q2 2025), and 342657.14% (Q1 2025).